Article originally published in Journal of European Competition Law & Practice Advance Access on July 31, 2012

This survey article discusses the major EU competition law developments in the pharmaceutical sector from 1 July 2011 through 30 June 2012. The developments during this period were largely incremental, but presage what is likely to be a year of increased enforcement activity. The Advocate General’s opinion in AstraZeneca may well be the harbinger of a Court of Justice judgment that upholds the General Court’s judgment and, thus, provides the European Commission with a favourable precedent that will undoubtedly encourage its enforcement efforts. The Commission continues to investigate cases dealing with reverse-payment patent settlements, and the coming months could well see a step up in activity in these cases. Recently, the Commission has indicated a renewed interest in parallel trade, particularly dual pricing arrangements in Spain, which may signal a greater focus on vertical issues more generally, an area where the Commission has been criticized for largely leaving the field to the national competition authorities and courts in recent years.

Read the complete article here